Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.
about
The therapeutic potential of metal-based antimalarial agents: implications for the mechanism of actionThe clinical development process for a novel preventive vaccine: An overviewThe March Toward Malaria VaccinesPotential public health impact of RTS,S malaria candidate vaccine in sub-Saharan Africa: a modelling studyEfficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sitesThe public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models.Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.Cost-effectiveness analysis of vaccinating children in Malawi with RTS,S vaccines in comparison with long-lasting insecticide-treated nets.Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine InfectionAssessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient careEfficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.Genetic variation in the Plasmodium falciparum circumsporozoite protein in India and its relevance to RTS,S malaria vaccine.Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children.Lessons from malaria control to help meet the rising challenge of dengue.Preparing for future efficacy trials of severe malaria vaccinesPlasmodium falciparum malaria vaccines: current status, pitfalls and future directions.Vaccine Development and Trials in Low and Lower Middle Income Countries: Key issues, advances and future opportunities.The march toward malaria vaccines.Emergence of Community-Acquired, Multidrug-Resistant Invasive Nontyphoidal Salmonella Disease in Rural Western Kenya, 2009-2013.Deciphering assumptions about stepped wedge designs: the case of Ebola vaccine research.Analysis of the immune response of a new malaria vaccine based on the modification of cryptic epitopes.Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum.Longitudinal estimation of Plasmodium falciparum prevalence in relation to malaria prevention measures in six sub-Saharan African countries.Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium.A study of the anti-plasmodium activity of angiotensin II analogs.The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination.Le vaccin antipaludique RTS,S/AS01 chez les enfants âgés de 5 à 17 mois au moment de la première vaccination
P2860
Q20906133-913B12E4-3BD6-4CE5-A58B-EBFAC16A0A87Q26770871-E512596A-97EB-433E-A4A3-A832AEEB3DA6Q28084325-31AF2B64-6E85-4185-B9F2-F76D2276BB08Q28397448-B19CFB9A-DCB2-464B-94CF-C8E1A80D95A0Q28541281-EB385A0D-6564-4B9A-8C97-AE7D8FCCFEDBQ30983587-75B27A29-F5E1-4787-A42E-F155BCDC296BQ33577093-7BF4B5F5-9FFA-4CBA-A9B3-D102DEBFFCE8Q33590453-E2BB3B49-EDB8-4BCB-B0AA-5BF7A3C24C6CQ33737949-644043D0-D932-4643-91CC-57B3398BC3B1Q33981953-F0CAE2A0-A7E9-4EA3-B960-58798C07817BQ34043843-AD74D440-D600-4C86-BB15-412A52EE3F80Q34389610-16705B80-8D88-4B3A-9B63-4B43B9E8FAB4Q35198729-DB368E8E-052A-41E1-91AB-186C51D0B69AQ36615111-9488D6E3-6F46-4BD0-9765-E39EE70F58F8Q36717129-E222C207-C30C-4E4C-A944-A4E8E434B953Q38059751-03786184-7611-49B2-9C71-D333E7BBA749Q38369368-00564E14-1B5B-4F67-89A0-CE0F77CEFD81Q38577638-F6E12A58-9800-4703-895B-1160AD132BC2Q38602713-27B7D11E-25F9-420A-BDDC-62462F64FF58Q38984060-E010EDD1-5482-4ED4-8CF9-C67E93869BD2Q40809441-59F6D82F-663D-4D61-94D0-878D07DC8629Q42126049-38A87514-84C0-4B62-AD39-122981000EA5Q43032696-ABCD00EE-A514-48FE-B2B3-9FB999473B6AQ47106697-37C8B2E6-2E68-4CE2-85C5-F8213B2FD68BQ47831567-0EA84541-9430-4E85-B28D-13BE58AB42F1Q47977891-6AF98D3D-6181-4791-9A0C-742148BF697BQ58131059-572DC77E-32C6-4116-84ED-58AB9C4A4875
P2860
Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Design of a phase III multicen ...... ansmission settings in Africa.
@ast
Design of a phase III multicen ...... ansmission settings in Africa.
@en
type
label
Design of a phase III multicen ...... ansmission settings in Africa.
@ast
Design of a phase III multicen ...... ansmission settings in Africa.
@en
prefLabel
Design of a phase III multicen ...... ansmission settings in Africa.
@ast
Design of a phase III multicen ...... ansmission settings in Africa.
@en
P2093
P2860
P50
P921
P356
P1433
P1476
Design of a phase III multicen ...... ansmission settings in Africa.
@en
P2093
Amanda Leach
Barbara Savarese
Christian Loucq
Clinical Trials Partnership Committee
Conor Cahill
Eusebio Macete
Johan Vekemans
Marc Lievens
Opokua Ofori-Anyinam
Patricia Njuguna
P2860
P2888
P356
10.1186/1475-2875-10-224
P577
2011-08-04T00:00:00Z
P5875
P6179
1027763646